missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Enfortumab Recombinant Human Monoclonal Antibody
Descripción
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Enfortumab vedotin is an antibody-pharmaceutical conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to brentuximab vedotin, another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name PadcevTM.
Especificaciones
Especificaciones
| Antígeno | Enfortumab |
| Aplicaciones | ELISA |
| Clasificación | Recombinant Monoclonal |
| Concentración | 1 mg/mL |
| Conjugado | Unconjugated |
| Formulación | PBS with no preservative; pH 7.4 |
| Alias de gen | AGS-22C3; AGS-22CE; AGS-22M; AGS-22M6E; AGSM6 |
| Especie del huésped | Human |
| Inmunógeno | Human PVRL4. |
| Método de purificación | Protein A/G |
| Mostrar más |
Título del producto
Al hacer clic en Enviar, acepta que Fisher Scientific se ponga en contacto con usted en relación con los comentarios que ha proporcionado en este formulario. No compartiremos su información para ningún otro fin. Toda la información de contacto proporcionada se mantendrá de acuerdo con nuestra Política de Privacidad. Política de privacidad.
¿Detecta una oportunidad de mejora?